Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure

Antoni Bayes-Genis, Marta De Antonio, Amparo Galán, Héctor Sanz, Agustin Urrutia, Roser Cabanes, Lucía Cano, Beatriz González, Cristanto Díez, Teresa Pascual, Roberto Elosúa, Josep Lupón

Research output: Contribution to journalArticleResearchpeer-review

97 Citations (Scopus)

Abstract

Aims To address the incremental usefulness of biomarkers from different disease pathways for predicting risk of death in heart failure (HF). Methods and results We used data from consecutive patients treated at a structured multidisciplinary HF unit to investigate whether a combination of biomarkers reflecting ventricular fibrosis, remodelling, and stretch [ST2 and N-terminal pro brain natriuretic peptide (NTproBNP)] improved the risk stratification of a HF patient beyond an assessment based on established mortality risk factors (age, sex, ischaemic aetiology, left ventricular ejection fraction, New York Heart Association functional class, diabetes, glomerular filtration rate, sodium, haemoglobin, and beta-blocker and angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatments). ST2 was measured with a novel high-sensitivity immunoassay. During a median follow-up time of 33.4 months, 244 of the 891 participants in the study (mean age 70.2 years at baseline) died. In the multivariable Cox proportional hazards model, both ST2 and NTproBNP significantly predicted the risk of death. The individual inclusion of ST2 and NTproBNP in the model with established mortality risk factors significantly improved the C statistic for predicting death [0.79 (0.76-0.81); P < 0.001]. The net improvement in reclassification after the separate addition of ST2 to the model with established risk factors and NTproBNP was estimated at 9.90% [95% confidence interval (CI) 4.34-15.46; P < 0.001] and the integrated discrimination improvement at 1.54 (95% CI 0.292.78); P 0.015). ConclusionsOur data suggest that in a real-life cohort of HF patients, the addition of ST2 and NTproBNP substantially improves the risk stratification for death beyond that of a model that is based only on established mortality risk factors. © 2011 The Author.
Original languageEnglish
Pages (from-to)32-38
JournalEuropean Journal of Heart Failure
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2012

Keywords

  • Heart failure
  • Prognosis
  • ST2

Fingerprint Dive into the research topics of 'Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure'. Together they form a unique fingerprint.

  • Cite this